#Anixa Biosciences #Breast Cancer Vaccine #Patent Technology

Anixa Biosciences Granted Mexican Patent for Breast Cancer Vaccine

Anixa Biosciences, Inc. has recently announced a significant milestone in its quest to combat breast cancer— the issuance of a patent by the Mexican Institute of Industrial Property (IMPI) for its breast cancer vaccine technology. This patent, numbered 432748, protects critical components of the vaccine, extending its intellectual property rights in Mexico until 2040. This news not only represents a major achievement for Anixa but also reflects the increasing recognition of the innovative approaches companies are taking to fight cancer on a global scale.

Dr. Amit Kumar, CEO and Chairman of Anixa, expressed his enthusiasm regarding this patent, emphasizing that it further underscores the novelty and potential of their breast cancer vaccine technology. As the company progresses through clinical development in the United States, this strengthened global patent portfolio will enhance their ability to forge international partnerships, possibly with major pharmaceutical companies aimed at further commercializing their innovative solution.

Innovative Vaccine Approach

The breast cancer vaccine developed by Anixa in collaboration with the Cleveland Clinic takes a novel approach by focusing on immunizing individuals against a protein known as human α-lactalbumin. This protein is typically linked to lactation but is also found to be aberrantly expressed in certain types of breast cancer. By utilizing a vaccine aimed at this